RESOLVE (202047)

  https://cordis.europa.eu/project/id/202047

  FP7 (2007-2013)

  Resolve Chronic Inflammation and Achieve Healthy Aging by Understanding Non-regenerative Repair

  Termination of developmental processes and their reactivation in adult life (HEALTH-2007-2.2.2-2)

  pathology

  2008-04-01 Start Date (YY-MM-DD)

  2013-09-30 End Date (YY-MM-DD)

  € 14,173,960 Total Cost


  Description

RESOLVE has been outlined to better understand the regulatory networks that control the devel-opmental processes in organ repair and to identify mechanisms which cause the termination of regu-lar organ development leading to fibroproliferative wound healing. Fibroproliferative wound healing represents a major pathology in elderly people shifting regular organ development into progressive organ fibrosis with complete loss of organ function. Based on the identification of valuated molecu-lar targets of fibroproliferative repair, RESOLVE aims to create suitable treatment strategies to achieve healthy ageing in the elderly. In doing so, RESOLVE will create a significant impact on life quality of elderly people. RESOLVE’s outcomes will strengthen the competitiveness of European science and biotechnology industry and contribute to cost saving strategies in the health care sector. RESOLVE’s structured scientific approach combines as yet fragmented fields of research using model organisms which represent (a) different forms of wound healing, (b) different human diseases and (c) different genetic backgrounds, guaranteeing social and scientific relevance, modularity of re-search and the integration of existing biological knowledge, technical expertise and medical experi-ence. In addition, sequential generation of data during improvement or worsening ensures clinical relevance and leads to a stringent exploitation strategy. The sustainable outcomes of RESOLVE’s efforts will be: (A) the urgently needed diagnostic tool for fibroproliferative wound healing in various organs, (B) highly valuable transgenic animals offering test systems for fibroproliferative wound healing, and (C) a characterization of compounds capable of interfering with targets involved in fibroprolifera-tive repair.


  Complicit Organisations

1 Israeli organisation participates in RESOLVE.

Country Organisation (ID) VAT Number Role Activity Type Total Cost EC Contribution Net EC Contribution
Austria MEDIZINISCHE UNIVERSITAET WIEN (999989976) ATU57469858 coordinator HES € 0 € 2,816,568 € 0
Austria BRIGITTE ROHNER (999728949) nan participant PRC € 0 € 37,278 € 0
Italy UNIVERSITA DEGLI STUDI DI VERONA (999838074) IT01541040232 participant HES € 0 € 445,051 € 0
Austria AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH (999584128) ATU14703506 participant REC € 0 € 2,427,159 € 0
Belgium UNIVERSITE CATHOLIQUE DE LOUVAIN (999980664) BE0419052272 participant HES € 0 € 573,135 € 0
Israel BEN-GURION UNIVERSITY OF THE NEGEV (999846222) IL500701644 participant HES € 0 € 456,628 € 0
Hungary BIOTALENTUM TUDASFEJLESZTO KFT (999925665) HU13519027 participant PRC € 0 € 676,953 € 0
Germany CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL (999839529) DE811317279 participant HES € 0 € 537,046 € 0
Poland INSTYTUT MEDYCYNY WSI IM WITOLDA CHODZKI (999553282) nan participant REC € 0 € 399,920 € 0
Spain AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (999991722) ESQ2818002D participant REC € 0 € 298,886 € 0
Spain INTEGROMICS SL ITG (999713817) nan participant PRC € 0 € 528,465 € 0
Italy POLITECNICO DI TORINO (999977754) IT00518460019 participant HES € 0 € 317,275 € 0
United Kingdom UNIVERSITY OF BRISTOL (999974262) GB991261800 participant HES € 0 € 841,441 € 0
Austria PUNKT INTERNATIONAL GMBH (989991701) nan participant PRC € 0 € 333,906 € 0